Complete Response Letter (CRL)
What is Complete Response Letter (CRL)?
FDA notification that the agency will not approve a drug application in its current form, citing specific deficiencies.
Why does Complete Response Letter (CRL) matter?
A Complete Response Letter (CRL) is FDA's way of saying "no, not yet" to a drug application. It's not a final rejection — it identifies specific issues the company must address before resubmission.
CRLs are devastating for biotech companies. A single CRL can wipe billions from market cap in minutes. The company must then decide whether to conduct additional studies, provide more data, or withdraw the application entirely.
Common CRL reasons include manufacturing deficiencies (GMP issues at production facilities), insufficient clinical data, safety concerns, or labeling problems.
Resubmission after a CRL triggers a new review cycle, typically 6-12 months.
Related terms
Recent coverage
- Merck Hits 55% NSCLC ORR With MK-2010, Won't Commit to Phase 3 Apr 18
- FDA Cleared Foundayo With 3 Postmarketing Safety Study Requirements Apr 15
- GSK Races mo-rez Into 5 Phase 3 Trials After 62% Ovarian ORR Apr 13
- FDA Sets First Formal Rules for Form 483 Responses Apr 9
- Amgen's $27.8B Drug Gets Easier — Tepezza Shot Matches IV Apr 6
The daily brief, 7am ET.
Every morning. The observations you'd rather not receive — before they hit your desk.
Request early access →hello@the483.com · Free